Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2023-08-17 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received sANDA approval for a specific pharmaceutical product (Tacrolimus Ointment, 0.03%). It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a media release about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4067 characters, which is relatively short and typical for a press release. There is no detailed financial data, no meeting materials, no voting results, no audit information, no legal proceedings, and no capital structure changes. This fits best under the category of a Regulatory Filing (RNS), which is a general category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2023-08-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges confirming the uploading of the audio recording of the Q1 FY 2023-24 Earnings Call on the company's website. It references the SEBI Listing Obligations and Disclosure Requirements, indicating a regulatory compliance announcement. The document does not contain the transcript or financial data itself but merely informs about the availability of the earnings call recording. The document length is short (1554 characters), and it is an announcement rather than the actual earnings release or call transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the earnings call recording availability, not the earnings release or call transcript itself.
2023-08-14 English
Financial Result Updates
Regulatory Filings
2023-08-11 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a certified copy of the minutes of a resolution passed by postal ballot through remote e-voting by shareholders of Glenmark Pharmaceuticals Limited. It details the voting results and the resolution regarding the re-appointment of an executive director and CFO. The document is addressed to stock exchanges and includes procedural details about the voting process and the resolution text. It does not contain financial statements or performance data, nor is it a report or presentation. It is an official announcement of the voting results and the resolution passed by shareholders. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a mere announcement of a report but the actual voting results and minutes. Confidence is high due to clear alignment with the DVA category.
2023-08-09 English
Shareholders meeting
Regulatory Filings
2023-08-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is an invitation to an earnings call scheduled for August 14, 2023, for Glenmark Pharmaceuticals' Q1 FY 2023-24 results. It includes dial-in numbers and contact information for registration. There is no actual financial data or detailed financial report content in the text. The document is a notice about the upcoming earnings call, not the transcript or the earnings release itself. Therefore, it fits the category of a Call Transcript (CT) invitation or announcement. However, since it is only an invitation and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event.
2023-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.